Clinical Trials Logo

Advanced Melanoma clinical trials

View clinical trials related to Advanced Melanoma.

Filter by:

NCT ID: NCT01621490 Completed - Metastatic Melanoma Clinical Trials

PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma

PD-1
Start date: September 27, 2012
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate pharmacodynamic changes of Nivolumab and Nivolumab in combination with Ipilimumab treatment on the biomarkers measured in the peripheral blood and tumor tissues of subjects with advanced melanoma (unresectable or advanced)

NCT ID: NCT01618136 Completed - Ovarian Cancer Clinical Trials

An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors

Start date: January 2012
Phase: Phase 1/Phase 2
Study type: Interventional

Overall Design: This is a multicenter, open-label, Phase 1/2 study which will be conducted in three arms (as described below). Each arm will be conducted in two parts: a Phase 1 part which will include dose escalation and a Phase 2 part which will include four cohorts in specific disease indications. Phase 1 will also include a food effect study of E7449 as a single agent. Once the MTD in the Phase 1 single agent arm and the Phase 1 combination arms of this study has been achieved, the sponsor will submit the relevant safety information and recommended Phase 2 dose to the IRB/Health Authorities. Arm 1: E7449 will be administered as a single agent. Arm 2: E7449 will be administered in combination with TMZ. Arm 3: E7449 will be administered in combination with carboplatin and paclitaxel

NCT ID: NCT01064713 Completed - Cancer Clinical Trials

Phase II Study of Tesetaxel in Metastatic Melanoma

Start date: February 2010
Phase: Phase 2
Study type: Interventional

The goal of this clinical research study is to learn if tesetaxel can help to control metastatic melanoma. The safety of this drug will also be studied.

NCT ID: NCT00920907 Completed - Advanced Melanoma Clinical Trials

Comparison of Ipilimumab Manufactured by 2 Different Processes in Participants With Advanced Melanoma

Start date: August 2009
Phase: Phase 1
Study type: Interventional

The purpose of this clinical research study is to compare pharmacokinetics of ipilimumab manufactured by two different processes

NCT ID: NCT00796991 Completed - Advanced Melanoma Clinical Trials

Drug-Drug Interaction - 3 Arm - Carboplatin/Paclitaxel, Dacarbazine

Start date: February 2009
Phase: Phase 1
Study type: Interventional

The purpose of this clinical research study is to learn the pharmacokinetics of Ipilimumab when combined with Paclitaxel/Carboplatin or Dacarbazine

NCT ID: NCT00688090 Completed - Advanced Melanoma Clinical Trials

Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma.

Start date: June 2008
Phase: Phase 1
Study type: Interventional

A dose comparison of a multi-component active immunotherapy designed to stimulate an immune reaction to specific tumor associated antigens which are highly expressed on melanomas.

NCT ID: NCT00542893 Completed - Advanced Melanoma Clinical Trials

A Phase I, Randomized, Open-label, Cross-over, Pharmacokinetic Study of Genasense With and Without Dacarbazine

Start date: April 2006
Phase: Phase 1
Study type: Interventional

This clinical drug-drug interaction study is being conducted to evaluate the pharmacokinetics of dacarbazine(DTIC) when administered in combination with Genasense

NCT ID: NCT00197912 Completed - Advanced Melanoma Clinical Trials

Dendritic Cell Based Therapy of Malignant Melanoma

Start date: September 2004
Phase: Phase 1/Phase 2
Study type: Interventional

The aim of the study is to show if vaccination with autologous dendritic cells pulsed with peptides or tumor lysate in combination with adjuvant cytokines and Cyclophosphamide can induce a measurable immune response in patients with metastatic malignant melanoma, and to evaluate the clinical effect (objective response rate) of the vaccination regime.